PDS Biotechnology (PDSB) news
Recent news
PDS Biotechnology Corp - Stephan Toutain removed as chief operating officer effective August 21, 2026 - SEC filing
AInvest Wire · 5d agoPDS Biotechnology Corp - On Aug 6, approved reduction in force to align expenses with strategic priorities - SEC filing
PDS Biotechnology Corporation (Nasdaq: PDSB) announced on August 6, 2026, a reduction in force as part of a strategic initiative to align operating expenses with its long-term business priorities, according to a recent SEC filing . The move reflects the company’s ongoing efforts to manage costs…
AInvest Wire · 5d agoPDS Biotechnology Corp - to advance PDS0301 Phase 2B, seek partnerships for PDS0101 over next 18-24 months
AInvest Wire · Aug 11, 2026PDS Biotech announces strategic refocus prioritizing PDS0301 in metastatic colorectal cancer (MCRC) and partnership strategy for PDS0101
PDS Biotech (Nasdaq: PDSB) has announced a strategic refocus of its development pipeline, emphasizing its investigational therapy PDS0301 for the treatment of metastatic colorectal cancer (mCRC) and outlining a partnership strategy for its HPV-targeted immunotherapy PDS0101. The decision follows…
AInvest Wire · Aug 11, 2026ImportantPDS Biotechnology announces preliminary biomarker study results in subset of advanced HPV-positive head and neck cancer patients at ESMO
AInvest Wire · Oct 23, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.